Features

 
 
  • Cardioncology Aiming for Respect as Multidisciplinary Specialty The decision to stop or amend cancer therapy cannot be decided by one provider but must follow "a clear protocol" and "be done by real experts in the field using a multidisciplinary approach," an expert says.
  • Califf for Commish? Opposition Rocks Senate Confirmation Process Among the issues: Does Robert Califf's past work involving industry disqualify him for the top FDA post? Depends on who is asked; some say yes, and others say the relationships may be an asset.
  • Bring Back LDL Targets, Says CVS on Advent of PCSK9 Inhibitors Mega-prescription provider CVS Health has worries over costly overuse of PCSK9 inhibitors and wants a return to treatment-based LDL-C targets. Guideline authors say a return to LDL treatment thresholds isn't happening without better evidence.
  • What Now, ARNI? Experts Ponder Newly Arrived Heart-Failure Drug Although enthusiasm is widespread, "we aren't ready to offer this to everyone who comes to our office," says one expert. "Especially because we didn't have the benefit of an FDA panel review."
  • 'Guarded Enthusiasm' Builds for PCSK9 Inhibitors The excitement is real, but with next week's FDA advisory panels on two new PCSK9 inhibitors, physicians are starting to think through tough questions about how to actually use the agents in clinical practice.
  • Ivabradine (Corlanor) US Approval for HF 'Out of the Blue' Reactions to recent FDA approval of the drug, which lowers heart rate, include enthusiasm, cautious optimism, and concerns over the way the process was conducted, especially because of what was left out.
  • Protecting Physicians: Staff Safety Highlighted With Boston Shooting It's not just about protecting physicians on the front lines in the emergency department. The Boston shooting of Dr Michael Davidson is a grim reminder that clinicians and staff can be exposed to dangerous individuals.
  • Crowdsource the Integrity of Published CV Research? A Debate Players in a raucous controversy over discredited research, pulled papers, and beta-blocker guidelines propose that accountability for the medical literature's accuracy be spread around.
  • Dosing the NOACs in Atrial Fib: Can We Do Better? The next stage of new oral anticoagulant research in AF could explore innovative dosing strategies. But few expect a return to schemes as onerous as warfarin's regular INR monitoring.
  • Who's Watching? The Case for a Live Case Outcomes Registry A 2010 "code of conduct" for live case demos called for a registry of patient outcomes. Four years later, experts say live case outcomes are excellent but admit, no one is formally keeping track.
  • HFSA Penalizing 'Excess' HF Readmissions: Incentive or Distraction? One year after the CMS started docking hospitals that fail to meet 30-day HF readmission benchmarks, experts have plenty of suggestions for making this a more meaningful measure of quality care.
  • HFSA Penalizing "Excess' HF Readmissions: Incentive or Distraction? One year after the CMS started docking hospitals that fail to meet 30-day HF readmission benchmarks, experts have plenty of suggestions for making this a more meaningful measure of quality care.
  • Heart-smart diabetes drugs: Pipedream or possibility? The FDA states new diabetes drugs now need to show a lack of cardiovascular toxicity. Despite initial reservations, companies are cooperating, and some are even seeking the holy grail of cardioprotection.
  • JNC 8, ATP 4 Guidelines (Still) Soon to Be Released JNC 8 and ATP 4 are MIA. Should clinicians be POed? Here are explanation, speculation, and a little news about what all seem to agree is an unusually long delay in releasing NHLBI guidelines on risk-factor management.
  • Single-Drug Polypharmacy in Cardiovascular Disease Cardiovascular disease is the biggest epidemic the world has ever known, "bigger than HIV," affecting nearly one in three individuals. Given the magnitude of the epidemic and the ensuing worldwide shortage of cardiologists and specialists to treat cardiovascular morbidities, there is a need for new treatment paradigms, say researchers. That's where the polypill comes in.
  • Preventing Sudden Cardiac Death at the 2012 Olympic Games Approximately 17 000 athletes from 200 countries will descend on London next week for the 2012 Olympic Games. Medical teams, including a staff of cardiologists, have been preparing for years to ensure the games go off without a hitch; the last thing anyone wants is an athlete dying of sudden cardiac arrest with the whole world watching.
  • Multibiomarker inflammation test for heart risk prediction A Cleveland-based company is offering a multibiomarker inflammation test that it claims offers "additive and complementary insight into an individual's risk for heart disease and cardiac events." Experts who spoke with heartwire agree there is an urgent need for simple, precise prediction tools, but whether the time has come for a multimarker blood test that patients can pay
  • So Long, Plavix, What a Ride! Clopidogrel Patent Expires Expiration of the clopidogrel patent draws a close to a "fascinating era" in cardiovascular medicine, say experts, having had its largest impact in the ACS and poststenting settings. Yet even as the patent expires there remain some unanswered questions, particularly given the emergence of platelet function and genetic testing for clopidogrel metabolism.
  • Seeking Community in the LVAD Age For people living with a left ventricular assist device, knowing a few simple tricks can make life a bit easier. Others with LVADs make good teachers, but increasingly, LVAD recipients are looking online for answers to their questions.
  • Statin safety: Cardiologists respond to FDA's glucose, cognition warnings The poll was intended to assess physicians' concerns about the risk of diabetes in patients treated with statin therapy as well as the potential for cognitive changes; it is in response to recent labeling changes approved by the FDA. For both potential side effects, physician responses point to a disconnect between level of concern and what they are actually seeing in practice.